

**Supplemental Table S1: Baseline Characteristics of Included vs. Excluded patients**

	<b>INCLUDED</b>	<b>EXCLUDED</b>	<b>P-Value</b>
	<b>N=2867</b>	<b>N=1082</b>	
<b>Clinical Trial</b>			<b>&lt;0.001</b>
<b>MADIT-I (%)</b>	<b>176 (6.1)</b>	<b>20 (1.9)</b>	
<b>MADIT-II (%)</b>	<b>1080 (37.7)</b>	<b>152 (14.1)</b>	
<b>SCD-HeFT (%)</b>	<b>1611 (56.2)</b>	<b>910 (84.1)</b>	
<b>Therapy assignment</b>			<b>&lt;0.001</b>
<b>ICD (%)</b>	<b>1533 (53.5)</b>	<b>133 (12.3)</b>	
<b>Patient Demographics</b>			
<b>Age (mean, yrs)</b>	<b>61.0</b>	<b>60.6</b>	<b>0.32</b>
<b>Female Gender (%)</b>	<b>544 (19.0)</b>	<b>252 (23.3)</b>	<b>0.003</b>
<b>Race</b>			<b>0.02</b>
<b>White (%)</b>	<b>2336 (81.5)</b>	<b>849 (78.5)</b>	
<b>Black (%)</b>	<b>387 (13.5)</b>	<b>154 (14.2)</b>	
<b>Other (%)</b>	<b>144 (5.0)</b>	<b>79 (7.3)</b>	
<b>Comorbidities</b>			
<b>History of CHF(%)</b>	<b>1620 (56.5)</b>	<b>422 (39.0)</b>	<b>&lt;0.001</b>
<b>Hypertension (%)</b>	<b>1527 (53.3)</b>	<b>609 (56.3)</b>	<b>0.09</b>
<b>Diabetes (%)</b>	<b>877 (30.6)</b>	<b>335 (31.0)</b>	<b>0.85</b>
<b>Cardiac Disease characteristics</b>			
<b>LVEF % (mean)</b>	<b>23.7</b>	<b>23.7</b>	<b>0.75</b>
<b>Prior CABG (%)</b>	<b>1148 (40.0)</b>	<b>319 (29.5)</b>	<b>&lt;0.001</b>
<b>Left BBB (%)</b>	<b>557 (20.0)</b>	<b>227 (21.3)</b>	<b>0.35</b>
<b>NYHA class</b>			<b>&lt;0.001</b>

<b>Class 1(%)</b>	<b>481 (16.8)</b>	<b>30 (2.8)</b>	
<b>Class 2(%)</b>	<b>1592 (55.5)</b>	<b>688 (64.5)</b>	
<b>Class 3(%)</b>	<b>794 (27.7)</b>	<b>296 (27.7)</b>	
<b>Medication use at enrollment</b>			
<b>Antiarrhythmic (%)</b>	<b>82 (2.9)</b>	<b>853 (78.8)</b>	<b>&lt;0.001</b>
<b>Beta-blockers (%)</b>	<b>1823 (63.6)</b>	<b>705 (65.2)</b>	<b>0.37</b>
<b>ACE inhibitor (%)</b>	<b>2482 (86.6)</b>	<b>1018 (94.1)</b>	<b>&lt;0.001</b>
<b>Estimated GFR</b>			
<b>Mean (ml/min)</b>	<b>68.7</b>	<b>68.1</b>	<b>0.48</b>
<b>GFR&lt;30 ml/min (%)</b>	<b>107 (3.7)</b>	<b>28 (2.7)</b>	<b>0.11</b>

**Abbreviations: LVEF, left ventricular ejection fraction; ICD, implantable cardioverter defibrillator; CHF, congestive heart failure; CABG, coronary artery bypass grafting; BBB, bundle branch block; NYHA, New York Heart Association; ACE, angiotension converting enzyme.**

**Supplemental Table S2: Baseline Characteristics of Patients Assigned to ICD vs. No ICD, eGFR>=60.**

	Assigned to ICD therapy N=992	Assigned to Control N=835	P-Value
<b>Clinical Trial</b>			<b>&lt;0.001</b>
MADIT-I (%)	50 (5.0)	47 (5.6)	
MADIT-II (%)	412 (41.5)	245 (29.3)	
SCD-HeFT (%)	530 (53.4)	543 (65.0)	
<b>Therapy assignment</b>			<b>&lt;0.001</b>
ICD (%)	992 (100.0)	0 (0)	
<b>Patient Demographics</b>			
Age (mean, yrs)	58.5	57.2	0.01
Female Gender (%)	175 (17.6)	156 (18.7)	0.58
Race			0.03
White (%)	806 (81.3)	654 (78.3)	
Black (%)	146 (14.7)	124 (14.9)	
Other (%)	40 (4.0)	57 (6.8)	
<b>Comorbidities</b>			
History of CHF(%)	591 (59.6)	405 (48.5)	<0.001
Hypertension (%)	491 (49.6)	415 (49.7)	1
Diabetes (%)	271 (27.3)	237 (28.4)	0.64
<b>Cardiac Disease characteristics</b>			
LVEF % (mean)	23.65	23.9	0.35
Prior CABG (%)	375 (37.8)	283 (33.9)	0.09
Left BBB (%)	186 (19.1)	155 (18.8)	0.90

<b>NYHA class</b>			<b>0.02</b>
Class 1(%)	193 (19.5)	125 (15.0)	
Class 2(%)	562 (56.7)	521 (62.4)	
Class 3(%)	237 (23.9)	189 (22.6)	
<b>Medication use at enrollment</b>			
Antiarrhythmic (%)	17 (1.7)	27 (3.2)	0.05
Beta-blockers (%)	661 (66.6)	548 (65.6)	0.66
ACE inhibitor (%)	853 (86.0)	767 (91.9)	<0.001
<b>Estimated GFR</b>			
Mean (ml/min)	82.4	81.4	0.18
GFR<30 ml/min (%)	0 (0)	0 (0)	

**Abbreviations: LVEF, left ventricular ejection fraction; ICD, implantable cardioverter defibrillator; CHF, congestive heart failure; CABG, coronary artery bypass grafting; BBB, bundle branch block; NYHA, New York Heart Association; ACE, angiotension converting enzyme.**

**Supplemental Table S3: Baseline Characteristics of Patients Assigned to ICD vs. No ICD, eGFR<60.**

	Assigned to ICD therapy  N=541	Assigned to Control  N=499	P-Value
<b>Clinical Trial</b>			<b>0.01</b>
MADIT-I (%)	35 (6.5)	44 (8.8)	
MADIT-II (%)	243 (44.9)	180 (36.1)	
SCD-HeFT (%)	263 (48.6)	275 (55.1)	
<b>Therapy assignment</b>			
ICD (%)	541 (100.0)	0 (0)	<0.001
<b>Patient Demographics</b>			
Age (mean, yrs)	67.1	66.2	0.13
Female Gender (%)	117 (21.6)	96 (19.2)	0.36
Race			0.75
White (%)	459 (84.8)	417 (83.6)	
Black (%)	60 (11.1)	57 (11.4)	
Other (%)	22 (4.1)	25 (5.0)	
<b>Comorbidities</b>			
History of CHF(%)	346 (64.0)	278 (55.7)	0.01
Hypertension (%)	327 (66.2)	294 (59.0)	0.66
Diabetes (%)	183 (33.8)	186 (37.4)	0.24
<b>Cardiac Disease characteristics</b>			
LVEF % (mean)	23.5	23.5	0.89
Prior CABG (%)	266 (49.2)	224 (44.9)	0.17
Left BBB (%)	115 (22.4)	101 (21.0)	0.59

<b>NYHA class</b>			<b>0.68</b>
Class 1(%)	82 (15.2)	81 (16.2)	
Class 2(%)	261 (48.2)	248 (49.7)	
Class 3(%)	198 (36.6)	170 (34.1)	
<b>Medication use at enrollment</b>			
Antiarrhythmic (%)	12 (2.2)	26 (5.2)	0.01
Beta-blockers (%)	330 (61.0)	284 (56.9)	0.19
ACE inhibitor (%)	452 (83.6)	410 (82.2)	0.57
<b>Estimated GFR</b>			
Mean (ml/min)	45.3	45.5	0.70
GFR<30 ml/min (%)	53 (9.8)	54 (10.8)	0.79

**Abbreviations:** LVEF, left ventricular ejection fraction; ICD, implantable cardioverter defibrillator; CHF, congestive heart failure; CABG, coronary artery bypass grafting; BBB, bundle branch block; NYHA, New York Heart Association; ACE, angiotension converting enzyme.